EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer

Lotte G Zuur iD, Denise S Hoogenkamp iD, Esmée C A van der Sar iD, Debra van Asten iD, Marnix G E H Lam, Jochem R N van der Voort-van Zyp, Pim J van Leeuwen, Berlinda J de Wit-van der Veen iD, Daphne M V de Vries-Huizing iD, Jeroen J M A Hendrikx, Arthur J A T Braat iD, Wouter V Vogel iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-07956-6 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Lotte G Zuur und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma B.V..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates. Adding [177Lu]Lu-PSMA-617 may improve tumour control and reduce reliance on long-term ADT. This phase-1 dose-escalation study explores the safety and tolerability of adding concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT. METHODS: In the multi-centre phase-1 dose-escalation study (PROQURE-I), treatment-naïve cT1-4N1M0 PCa patients received standard locoregional EBRT (25-35 fractions) and 2-3 years ADT with concurrent [177Lu]Lu-PSMA-617 to determine its maximum tolerated dose (MTD). Dose levels included one cycle (3, 6 or 9 GBq in week 2 of EBRT) or two cycles (2 × 7.4 GBq in week 2 and 4). Grade ≥ 3 toxicity (CTCAE v5.0) was dose-limiting. Tumour and organ dosimetry was performed with SPECT/CT and planar imaging at 4, 24 and 168 h post-injection. RESULTS: Fourteen patients were included. No dose-limiting toxicity was observed and the MTD was not reached. Reported grade 1-2 toxicities were related to EBRT. Median absorbed dose to the primary tumour of 0.71 Gy/GBq (interquartile range (IQR) 0.5-2.9) at the 9 GBq; 0.91 Gy/GBq (IQR 0.6-1.0) at 7.4 GBq cycle 1; and 0.47 Gy/GBq (0.3-0.5) at cycle 2. CONCLUSIONS: Concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT is safe and well tolerated in treatment-naïve N1M0 PCa. Clinical efficacy should be evaluated in a subsequent phase 2 study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsDipeptidesHeterocyclic Compounds, 1-RingLutetiumRadioisotopesAndrogen AntagonistsMaleHumansAgedMiddle AgedProstate-Specific Antigen

Stichwörter der Autor:innen

CurativeLutetium-177-PSMANode-positivePhase 1Prostate cancer radiotherapy

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumRadioisotopesAndrogen AntagonistsLutetium-177PSMA-617lutetium (177Lu) vipivotide tetraxetanProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • Department of Clinical Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands. w.vogel@nki.nl.

ORCID-Profile: Lotte G Zuur, Denise S Hoogenkamp, Esmée C A van der Sar, Debra van Asten, Berlinda J de Wit-van der Veen, Daphne M V de Vries-Huizing, Arthur J A T Braat, Wouter V Vogel

Förderung

  • Novartis Pharma B.V.

Zitieren

APA

Zuur, L. G., Hoogenkamp, D. S., van der Sar, E. C. A., van Asten, D., Lam, M. G. E. H., van der Voort-van Zyp, J. R. N., van Leeuwen, P. J., de Wit-van der Veen, B. J., de Vries-Huizing, D. M. V., Hendrikx, J. J. M. A., Braat, A. J. A. T., & Vogel, W. V. (2026). PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07956-6

Vancouver

Zuur LG, Hoogenkamp DS, van der Sar ECA, van Asten D, Lam MGEH, van der Voort-van Zyp JRN, et al. PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07956-6

BibTeX
@article{Zuur2026,
  author = {Zuur, Lotte G and Hoogenkamp, Denise S and van der Sar, Esmée C A and van Asten, Debra and Lam, Marnix G E H and van der Voort-van Zyp, Jochem R N and van Leeuwen, Pim J and de Wit-van der Veen, Berlinda J and de Vries-Huizing, Daphne M V and Hendrikx, Jeroen J M A and Braat, Arthur J A T and Vogel, Wouter V},
  title = {PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-07956-6}
}
Kostenlos starten →